Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex

Ian N. Foltz, Sylvia Hu, Chadwick King, Xinle Wu, Chaofeng Yang, Wei Wang, Jennifer Weiszmann, Jennitte Stevens, Jiyun Sunny Chen, Noi Nuanmanee, Jamila Gupte, Renee Komorowski, Laura Sekirov, Todd Hager, Taruna Arora, Hongfei Ge, Helene Baribault, Fen Wang, Jackie Sheng, Margaret KarowMinghan Wang, Yongde Luo, Wallace McKeehan, Zhulun Wang, Murielle M. Véniant, Yang Li

Research output: Contribution to journalArticle

122 Scopus citations

Abstract

Fibroblast growth factor 21 (FGF21) is a distinctive member of the FGF family with potent beneficial effects on lipid, body weight, and glucose metabolism and has attracted considerable interest as a potential therapeutic for treating diabetes and obesity. As an alternative to native FGF21, we have developed a monoclonal antibody, mimAb1, that binds to bKlotho with high affinity and specifically activates signaling from the βKlotho/FGFR1c (FGF receptor 1c) receptor complex. In obese cynomolgus monkeys, injection of mimAb1 led to FGF21- like metabolic effects, including decreases in body weight, plasma insulin, triglycerides, and glucose during tolerance testing. Mice with adipose-selective FGFR1 knockout were refractory to FGF21-induced improvements in glucose metabolism and body weight. These results in obese monkeys (with mimAb1) and in FGFR1 knockout mice (with FGF21) demonstrated the essential role of FGFR1c in FGF21 function and suggest fat as a critical target tissue for the cytokine and antibody. Because mimAb1 depends on bKlotho to activate FGFR1c, it is not expected to induce side effects caused by activating FGFR1c alone. The unexpected finding of an antibody that can activate FGF21-like signaling through cell surface receptors provided preclinical validation for an innovative therapeutic approach to diabetes and obesity.

Original languageEnglish (US)
Article number162ra153
JournalScience Translational Medicine
Volume4
Issue number162
DOIs
StatePublished - Nov 28 2012

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., Gupte, J., Komorowski, R., Sekirov, L., Hager, T., Arora, T., Ge, H., Baribault, H., Wang, F., Sheng, J., ... Li, Y. (2012). Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. Science Translational Medicine, 4(162), [162ra153]. https://doi.org/10.1126/scitranslmed.3004690